Home Business Tech Markets Entrepreneurs Leadership Personal Finance ForbesLife Lists Opinions Blogs E-mail Newsletters People Tracker Portfolio Tracker Special Reports Video & Audio Commerce Energy Health Care Logistics Manufacturing Services Technology Washington CIO Network Digital Entertainment Enterprise Tech Infoimaging Intelligent Infrastructure Personal Tech Sciences & Medicine Bonds Commodities Currencies Economy Emerging Markets Equities Finance Human Resources Law & Taxation Sales & Marketing Management Technology Careers Compensation Corporate Citizenship Corporate Governance Managing Philanthropy CEO Network Reference Estate Planning Funds Investment Newsletters Retirement Strategies Taxes Collecting Health Real Estate Sport Travel Vehicles Wine & Food 100 Top Celebrities 400 Richest Americans Largest Private Cos World's Richest People All Forbes Lists Business Opinions Investing Technology Opinions Washington & The World Companies People Reference Technology Companies Events People Reference
  

Pharmaceuticals
Is Caremark Rx Deal Good For Big Pharma?
Matthew Herper, 09.03.03, 11:55 AM ET

NEW YORK - Late Tuesday, Caremark Rx announced plans to buy rival pharmacy benefits manager AdvancePCS for $5 billion in stock and cash. Like other PBMs, the combined company will negotiate with drugmakers to get lower prices for prescription drugs for health insurers and employers. What effect, then, will the merger have on drug manufacturers such as Pfizer, Merck or Bristol-Myers Squibb?

At first glance, an obvious result of PBM consolidation might seem to be merely lowered drug prices. That would be bad news for big pharmaceutical firms. Combined, Caremark Rx (nyse: CMX - news - people ) and AdvancePCS (nasdaq: ADVP - news - people ) would have more dealing power. This could be accentuated by the fact that the new PBM will have only two large competitors: Medco Health Solutions (nyse: MHS - news - people ) and Express Scripts (nadsaq: ESRX - news - people ). But first impressions can be deceiving.

Increased pricing pressure could certainly be an issue for drugmakers, says C.J. Sylvester, a pharmaceuticals analyst at UBS. But PBMs can have a positive impact for drug companies as well, he says, by encouraging patients to stay on their drugs. In some instances, a nurse calls patients to remind them to refill their prescriptions.

"Pharma's biggest issue is getting patients more compliant," says Sylvester, who does not own stock in any of the drug companies he covers.

If PBMs do cause drug prices to go down, consolidation may not be the culprit. If a Medicare prescription drug benefit is passed and the government buys drugs through PBMs, the price of widely used pills could decrease, Sylvester says. Of course, this would also increase the number of people taking these medicines. Some analysts have speculated that such a plan could be good for the drug industry, at least in the short term.

Right now, the effect of today's merger on major drugmakers may be too close to call.


1 of 1


Article Controls



Related Sections
Home > Business > HealthCare



News Headlines | More From Forbes.com | Special Reports
   
Subscriptions >

Free Trial Issue of Forbes Forbes Gift Subscription
Subscribe To Newsletters Subscriber Customer Service
Buy Audio Version of Forbes




  
Trading Center
Brought to you by the sponsors below
 
 

CEO Book Club more >
The Philosopher Kings Of Hedging
The Philosopher Kings Of Hedging
Steven Drobny reveals insights from the hedge fund all-stars.
READ REVIEW          BUY THIS BOOK
Laissez Faire In The Studio
Dunstan Prial
At Columbia Records, John Hammond made some of the greatest discoveries in American music.
READ REVIEW          BUY THIS BOOK
Search Books


Advanced Search |  New & Notable

 
  
 
    

 
SitemapHelpContact UsInvestment NewslettersForbes ConferencesForbes MagazinesForbes Autos
Ad Information   Forbes.com Wireless   RSS   Reprints/Permissions   Subscriber Services  
© 2006 Forbes.com Inc.™   All Rights Reserved   Privacy Statement   Terms, Conditions and Notices


Stock quotes are delayed at least 15 minutes for Nasdaq, at least 20 minutes for NYSE/AMEX. U.S. indexes are delayed at least 15 minutes with the exception of Nasdaq, Dow Jones Industrial Average and S&P 500 which are 2 minutes delayed.


Powered By